TheraRadar
← Back
Data updated: Jun 28, 2026

GUARDIAN DRUG

Generics

GUARDIAN DRUG is a generic drug manufacturer focused on Infectious Disease, Cardiovascular, Gastroenterology.

1987
Since
5
Drugs
-
Trials
0
New Drugs (2yr)

GUARDIAN DRUG's Key Drugs

GUARDIAN DRUG's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

GUARDIAN DRUG's Recent FDA Approvals

New NDA/BLA approvals for GUARDIAN DRUG over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

GUARDIAN DRUG's Therapeutic Areas

GUARDIAN DRUG's approved drugs and pipeline span 3 therapeutic areas, led by Infectious Disease and Cardiovascular. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 33%
1 drugs
Cardiovascular 33%
1 drugs
Gastroenterology 33%
1 drugs

GUARDIAN DRUG's Top Competitors

GUARDIAN DRUG's closest competitors by therapeutic-area and drug-target overlap include APOTHECON, WAYLIS THERAP, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

GUARDIAN DRUG Pipeline Snapshot

Active clinical trials for GUARDIAN DRUG across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Infectious Disease pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling